Teriflunomide Inhibits Clinical Demyelinating Event in Patients With MS

Teriflunomide treatment incurred an unadjusted risk reduction of 63% and an adjusted risk reduction of 72% in inhibiting a first clinical demyelinating event in patients with multiple sclerosis (MS).

Related Keywords

,Radiologically Isolated Syndrome ,Multicenter Randomized Double Blinded Assessment ,First Attack ,Autoimmune ,Ms ,Multiple Sclerosis ,Teriflunomide ,Clinical Demyelinating Event ,Risk Reduction ,Iris ,